Oppenheimer Believes IART Won’t Stop Here

In a report released today, Steven Lichtman from Oppenheimer reiterated a Buy rating on Integra Lifesciences (NASDAQ: IART). The company’s shares opened today at $44.99, close to its 52-week high of $45.87.

According to TipRanks.com, Lichtman is ranked 0 out of 5 stars with an average return of -2.3% and a 54.9% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Wright Medical Group.

Integra Lifesciences has an analyst consensus of Strong Buy, with a price target consensus of $65.40.

Integra Lifesciences’ market cap is currently $3.23B and has a P/E ratio of 56.95. The company has a book value ratio of 3.9256.

Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is neutral on the stock. Most recently, in August 2016, Raymond Murphy, a Director at IART sold 2,600 shares for a total of $225,238.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Specialty Surgical Solutions, and Orthopedics and Tissue Technologies segments. The Specialty Surgical Solutions segment offers specialty surgical instrumentation for a broad range of specialties, such as products and solutions for dural repair, precision tools and instruments, tissue ablation, and neuro critical care. The Orthopedics and Tissue Technologies segment sells regenerative technology products that can be used to provide treatment for acute and chronic wounds, surgical tissue repair including hernia repair, peripheral nerve repair and protection, and tendon repair. It also sells hardware products, such as bone and joint fixation and joint replacement devices, implants and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, the foot, ankle, and leg below the knee. The company was founded by Richard E. Caruso in 1989 and is headquartered in Plainsboro, NJ.